Protalix Prices $23.6M Public Offering for ProCellEx Pipeline
By Catherine Shaffer
Friday, February 17, 2012
Protalix Biotherapeutics Inc., of Carmiel, Israel, priced a public offering of 4.5 million shares at $5.25 per share, a 14.3 percent discount to Wednesday's closing price, which will bring in about $23.6 million in gross proceeds.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.